Glucagon-like peptide-1 receptor agonists and the risk of obesity-related cancers: a systematic review and meta-analysis
Never dismiss persistent digestive symptoms as simply a side effect without professional evaluation, especially if they are new, severe, or accompanied by other concerning features
For retatrutide, monitoring should be more comprehensive because of the additional receptor targets
Limit: retatrutide is newer, with fewer long-term data (phase III ongoing, not yet published), and the glucagon arm imposes stricter ALT/AST follow-up
GIP Receptor Agonism Unlike early GLP-1 monotherapies, Retatrutide places a heavy emphasis on GIP receptor (GIPR) activity
Overview of GLP-1 Receptor Agonists for Weight Loss Receptor agonists that target the GLP-1 pathway play a crucial role in managing obesity and type 2 diabetes